The regulator has set a timeframe of 12th August for its review of the new drug application (NDA) and – if approved – brensocatib could become a much-needed treatment option for hundreds of ...

Johnson & Johnson has moved a step closer to filing a potential first-in-class therapy for psoriasis after the drug hit the mark in a phase 3 trial. Once-daily oral IL-23 inhibitor icotrokinra ...

ionic binding of drug and IL; (ii) covalent binding of drug and IL; and (iii) dual binding using both ionic and covalent approaches. Seven ionic liquids containing salicylic acid (SA-ILs) in the ...

‡ Nano-Biopolymers Research Laboratory, Department of Chemical Engineering, College of Engineering, University of Tehran, P.O. Box 11155-4563, Tehran, Iran Article Views are the COUNTER-compliant sum ...